Compare Stocks: ENLV, DTSQ, ONCY, and RANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTSQ DT Cloud Star Acquisition	$11.34 +0.3%	$11.32	$10.45 ▼ $12.90	$100.58M	-0.01	2,754 shs	2,175 shs
ENLV Enlivex Therapeutics	$1.73 +13.8%	$5.56	$1.47 ▼ $27.15	$26.58M	1.6	450,235 shs	290,091 shs
ONCY Oncolytics Biotech	$0.83 -1.6%	$0.86	$0.73 ▼ $1.51	$107.72M	1.13	815,072 shs	606,661 shs
RANI Rani Therapeutics	$0.92 +11.0%	$0.77	$0.44 ▼ $3.87	$102.25M	0.78	1.04 million shs	1.35 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTSQ DT Cloud Star Acquisition	0.00%	+0.22%	-0.04%	+1.16%	+8.46%
ENLV Enlivex Therapeutics	+13.82%	-5.98%	-62.72%	-83.99%	-89.02%
ONCY Oncolytics Biotech	-1.63%	+0.89%	-2.24%	+5.19%	-16.73%
RANI Rani Therapeutics	+11.05%	+14.18%	+33.56%	-14.34%	+66.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTSQ DT Cloud Star Acquisition	$11.34 +0.3%	$11.32	$10.45 ▼ $12.90	$100.58M	-0.01	2,754 shs	2,175 shs
ENLV Enlivex Therapeutics	$1.73 +13.8%	$5.56	$1.47 ▼ $27.15	$26.58M	1.6	450,235 shs	290,091 shs
ONCY Oncolytics Biotech	$0.83 -1.6%	$0.86	$0.73 ▼ $1.51	$107.72M	1.13	815,072 shs	606,661 shs
RANI Rani Therapeutics	$0.92 +11.0%	$0.77	$0.44 ▼ $3.87	$102.25M	0.78	1.04 million shs	1.35 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTSQ DT Cloud Star Acquisition	0.00%	+0.22%	-0.04%	+1.16%	+8.46%
ENLV Enlivex Therapeutics	+13.82%	-5.98%	-62.72%	-83.99%	-89.02%
ONCY Oncolytics Biotech	-1.63%	+0.89%	-2.24%	+5.19%	-16.73%
RANI Rani Therapeutics	+11.05%	+14.18%	+33.56%	-14.34%	+66.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	14,206.36% Upside
ONCY Oncolytics Biotech	2.67	Moderate Buy	$5.00	501.68% Upside
RANI Rani Therapeutics	2.67	Moderate Buy	$8.75	854.61% Upside

Current Analyst Ratings Breakdown

Latest ENLV, DTSQ, ONCY, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/18/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/25/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.05) per share	N/A
RANI Rani Therapeutics	$1.63M	69.66	N/A	N/A	$0.39 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	8/24/2026 (Estimated)
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	-2,185.97%	-442.99%	N/A
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)

Latest ENLV, DTSQ, ONCY, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	193.24	193.24
ONCY Oncolytics Biotech	N/A	1.35	1.35
RANI Rani Therapeutics	N/A	5.31	5.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTSQ DT Cloud Star Acquisition	N/A
ENLV Enlivex Therapeutics	1.02%
ONCY Oncolytics Biotech	6.82%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
DTSQ DT Cloud Star Acquisition	52.88%
ENLV Enlivex Therapeutics	12.28%
ONCY Oncolytics Biotech	0.10%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A
ENLV Enlivex Therapeutics	70	17.49 million	14.77 million	Optionable
ONCY Oncolytics Biotech	30	127.51 million	127.38 million	Not Optionable
RANI Rani Therapeutics	110	123.88 million	90.77 million	Optionable

ENLV, DTSQ, ONCY, and RANI Headlines

Recent News About These Companies

Rani Therapeutics (NASDAQ:RANI) Coverage Initiated at Chardan Capital

4 hours ago | americanbankingnews.com

Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

August 18 at 8:05 AM | marketbeat.com

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

August 16, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS

August 13, 2026 | marketbeat.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

August 13, 2026 | globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 10, 2026 | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

Rani Therapeutics (RANI) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Insider Selling: Rani Therapeutics (NASDAQ:RANI) CEO Sells 8,014 Shares

July 28, 2026 | marketbeat.com

Insider Buying: Rani Therapeutics (NASDAQ:RANI) Director Buys $24,840.00 in Stock

July 28, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Buys 35,000 Shares

July 28, 2026 | marketbeat.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics

July 10, 2026 | yicaiglobal.comY

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, DTSQ, ONCY, and RANI Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.34 +0.04 (+0.31%)

Closing price 08/19/2026 03:18 PM Eastern

Extended Trading

$11.34 0.00 (0.00%)

As of 08/19/2026 07:40 PM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

Enlivex Therapeutics NASDAQ:ENLV

$1.73 +0.21 (+13.82%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$1.73 0.00 (0.00%)

As of 06:37 AM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Oncolytics Biotech NASDAQ:ONCY

$0.83 -0.01 (-1.63%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$0.82 -0.01 (-0.84%)

As of 06:25 AM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Rani Therapeutics NASDAQ:RANI

$0.92 +0.09 (+11.05%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$0.93 +0.01 (+1.57%)

As of 06:38 AM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, DTSQ, ONCY, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, DTSQ, ONCY, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, DTSQ, ONCY, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, DTSQ, ONCY, and RANI Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

Enlivex Therapeutics NASDAQ:ENLV

Oncolytics Biotech NASDAQ:ONCY

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, DTSQ, ONCY, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, DTSQ, ONCY, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, DTSQ, ONCY, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV, DTSQ, ONCY, and RANI Company Descriptions

DT Cloud Star Acquisition NASDAQ:DTSQ

Enlivex Therapeutics NASDAQ:ENLV

Oncolytics Biotech NASDAQ:ONCY

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools